The Health Service Executive is considering whether to fund the weight-loss drug Mounjaro for patients in Ireland, according to reports from RTÉ.ie, The Journal and Cork Beo. The Irish Times has published an explainer on how GLP-1 medications work within the HSE system.
The Journal reported that the benefits of the drug could be described as "transformative," while Cork Beo said the HSE is in talks to cover Mounjaro for Irish patients. RTÉ.ie reported that the HSE will consider access to the medication.
GLP-1 medications are a class of drugs used for weight loss, and the Irish Times explainer sets out how they function under the State's health service. The reports do not specify a timeline for a decision or detail the terms of any funding arrangement.
The coverage centres on Mounjaro specifically, with several Irish outlets reporting on the HSE's review of whether the drug should be publicly funded. The Journal's report frames the potential benefits as significant, though the material available does not include figures on cost, eligibility or the number of patients who might be affected.
What to watch next: whether the HSE reaches a decision on funding Mounjaro, and what eligibility criteria would apply if it does.
